secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001213900-25-001408
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma reports LYMPHIR launch prep progress; targeting H1 2025 commercial launch
--------------------------------------------------------------------------------

- LYMPHIR approved Aug 2024 for relapsed/refractory CTCL; commercial launch targeted H1 2025.
- Secured commercial supply agreements with CMOs; first-year launch supply already produced.
- Submitted J-code application under HCPCS; secured inclusion in NCCN guidelines.
- Designing patient assistance program and building specialized sales team for CTCL providers.
- Exploring international licensing partnerships and expanded indications, including combination immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025001408/0001213900-25-001408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025001408/ea0226990-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-001408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer